RxDoctor Payments Data

Elizabeth Midney-Martinez, MD

Family Medicine · Labelle, FLNPI 1295149466

Payments from drug & device makers

$653in general payments, 2019–2025

Across 47 payments — averaging $13.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$518
  • AstraZeneca$72
  • Amarin Pharma, Inc.$25
  • Lilly USA, LLC$24
  • Merck$14

What the payments were for

  • Food & beverage$653100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk38$518
AstraZeneca5$72
Amarin Pharma, Inc.1$25
Lilly USA, LLC2$24
Merck1$14

How this compares

$653 in reported general payments places this provider in the 55th percentile of 7,282 family medicine providers in Florida.

See all family medicine providers in Florida

Medicare billing

Part B allowed, 2024
$24,570
Medicare patients
180
Services billed
305

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide224$282,025
MounjaroTirzepatide182$213,935
JardianceEmpagliflozin91$126,277
EliquisApixaban89$123,618
Tresiba Flextouch U-200Insulin Degludec48$44,414
Repatha SureclickEvolocumab26$39,031
Trelegy ElliptaFluticasone/Umeclidin/Vilanter29$33,612
Tresiba Flextouch U-100Insulin Degludec38$30,218
XareltoRivaroxaban29$29,642
TrulicityDulaglutide21$27,329
FarxigaDapagliflozin Propanediol22$21,420
LinzessLinaclotide12$17,164
MyrbetriqMirabegron12$16,596
Spiriva HandihalerTiotropium Bromide11$15,180
Breo ElliptaFluticasone/Vilanterol17$13,955

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$518$282,025224 claims
Lilly USA, LLCMounjaro, Trulicity$24$241,264203 claims
AstraZenecaFarxiga, Symbicort$72$24,41135 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 7,282 family medicine providers in Florida.

Other family medicine in Labelle

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →